Literature DB >> 3791059

Cell loss from the nucleus basalis of Meynert in Alzheimer's disease.

R Doucette, M Fisman, V C Hachinski, H Mersky.   

Abstract

We examined the degree of neuronal loss from the nucleus basalis of Meynert (nbM) in two groups of Alzheimer patients differing in the degree of intellectual impairment. Significant cell loss from the nbM was found only in the more severely demented group of patients. Mean cell counts (per 10 mu paraffin section) were compiled separately for the anterior, intermediate and posterior subdivisions of the human nbM in three groups of subjects: Group 1 (N = 4) was severely demented and was untestable on the Extended Scale for Dementia (ESD) for at least the last two years of life; Group 2 (N = 4) was less demented and had completed at least one ESD test within 12 months of death; Group 3 (five controls) had died of non-neurological causes. In Group 2 there was a small (but insignificant) trend toward cell loss in the anterior subdivision, and a normal complement of neurons in both the intermediate and posterior subdivisions. There was, however, significant cell loss from all subdivisions of Group 1. How these cell counts may relate to the severity of the dementia is discussed.

Entities:  

Mesh:

Year:  1986        PMID: 3791059     DOI: 10.1017/s0317167100037070

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  13 in total

Review 1.  Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease.

Authors:  A I Levey
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

2.  Neuropathological study on the nucleus basalis of Meynert in Pick's disease.

Authors:  K Mizukami; K Kosaka
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

Review 3.  Physostigmine for Alzheimer's disease.

Authors:  F Coelho; J Birks
Journal:  Cochrane Database Syst Rev       Date:  2001

4.  Tau Oligomer Pathology in Nucleus Basalis Neurons During the Progression of Alzheimer Disease.

Authors:  Chelsea T Tiernan; Elliott J Mufson; Nicholas M Kanaan; Scott E Counts
Journal:  J Neuropathol Exp Neurol       Date:  2018-03-01       Impact factor: 3.685

Review 5.  Genetic toxicology and toxicokinetics of arecoline and related areca nut compounds: an updated review.

Authors:  Nuno G Oliveira; Daniela L Ramos; Ricardo Jorge Dinis-Oliveira
Journal:  Arch Toxicol       Date:  2020-10-24       Impact factor: 5.153

6.  Expression of the CD15 epitope in the human magnocellular basal forebrain system.

Authors:  S A Morres; J K Mai; L Teckhaus
Journal:  Histochem J       Date:  1992-11

7.  HDAC2 dysregulation in the nucleus basalis of Meynert during the progression of Alzheimer's disease.

Authors:  L Mahady; M Nadeem; M Malek-Ahmadi; K Chen; S E Perez; E J Mufson
Journal:  Neuropathol Appl Neurobiol       Date:  2018-10-28       Impact factor: 8.090

8.  An automatic reaction control chemical ionization technique in ion trap detector for quantitative plasma profding of arecoline in treated alzheimer patients.

Authors:  H U Shetty; E M Daly; N H Greig; S I Rapoport; T T Soncrant
Journal:  J Am Soc Mass Spectrom       Date:  1991-04       Impact factor: 3.109

Review 9.  Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer's and Parkinson's disease.

Authors:  Alan King Lun Liu; Raymond Chuen-Chung Chang; Ronald K B Pearce; Steve M Gentleman
Journal:  Acta Neuropathol       Date:  2015-01-30       Impact factor: 17.088

Review 10.  Involvement of Cholinergic, Adrenergic, and Glutamatergic Network Modulation with Cognitive Dysfunction in Alzheimer's Disease.

Authors:  Yu-Jung Cheng; Chieh-Hsin Lin; Hsien-Yuan Lane
Journal:  Int J Mol Sci       Date:  2021-02-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.